CSL CEO Brian McNamee On Being Australia’s Only Homegrown MNC: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Australia's only homegrown multinational company in the pharmaceutical sector, CSL is at the forefront of producing a novel A H1N1 influenza vaccine, having signed a $180 million contract with U.S. Dept of Health and Human Services to provide the vaccine antigen in bulk form. CSL is also the originator of Merck's HPV vaccine Gardasil. CEO Brian McNamee talked with PharmAsia News' Australia bureau about CSL's operations at home and abroad.
You may also be interested in...
As “The Pink Sheet” team heads to BIO’s annual partnering convention in Chicago, the Russian government rejects Abbott’s bid for NGO Petrovax. Plus news on deals between Roche and Ascletis, Lilly and Siemens, and Santaris and Bristol-Myers.
PharmAsia News combs through earnings reports to bring you highlights on Australian biotech firms. We start with CSL Ltd, Acrux, Pharmaxis and Mesoblast for the period ended Dec. 31, 2012.
CSL CEO Brian McNamee On Being Australia's Only Homegrown MNC: An Interview With PharmAsia News (Part 2 of 2)
[Editor's note: This is part two of a two-part interview. Part one appeared in PharmAsia News, June 1, 2009.]